PMADS

Id:	acc1602
Group:	2sens
Protein:	CYLD
Gene Symbol:	CYLD
Protein Id:	Q9NQC7
Protein Name:	CYLD_HUMAN
PTM:	phosphorylation
Site:	Ser418
Site Sequence:	SLTTENRFHSLPFSLTKMPNT
Disease Category:	Cancer
Disease:	Lymphoma
Disease Subtype:	DLBCL
Disease Cellline:	HBL-1
Disease Info:
Drug:	rituximab
Drug Info:	"Rituximab is a chimeric murine/human monoclonal antibody targeting CD20 antigen, approved by the U.S. FDA in 1997 and developed by Roche Pharma (Schweiz) Ltd., primarily indicated for non-Hodgkin's lymphoma (NHL) and CD20-positive chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide."
Effect:	suppress
Effect Info:	BTK inhibitors can enhance rituximab-induced apoptosis of non-GCB-DLBCL cells by downregulating the phosphorylation of CYLD.
Note:
Score:	5.0
Pubmed(PMID):	33827598
Sentence Index:	33827598_11-12
Sentence:	"To verify the effect of BTKis on the phosphorylation of CYLD and the apoptosis in vivo and in rituximab resistant non-GCB-DLBCL, the xeograft model and rituximab resistant non-GCB-DLBCL cells were generated by tumor cell inoculation and escalation of drug concentrations, respectively. RESULTS: BTKis induced apoptosis by down-regulating CYLD phosphorylationin in non GCB-DLBCL, xenograft mouse model, and rituximab-resistant cells, and this effect could be enhanced by rituximab."

Sequence & Structure:

MSSGLWSQEKVTSPYWEERIFYLLLQECSVTDKQTQKLLKVPKGSIGQYIQDRSVGHSRIPSAKGKKNQIGLKILEQPHAVLFVDEKDVVEINEKFTELLLAITNCEERFSLFKNRNRLSKGLQIDVGCPVKVQLRSGEEKFPGVVRFRGPLLAERTVSGIFFGVELLEEGRGQGFTDGVYQGKQLFQCDEDCGVFVALDKLELIEDDDTALESDYAGPGDTMQVELPPLEINSRVSLKVGETIESGTVIFCDVLPGKESLGYFVGVDMDNPIGNWDGRFDGVQLCSFACVESTILLHINDIIPALSESVTQERRPPKLAFMSRGVGDKGSSSHNKPKATGSTSDPGNRNRSELFYTLNGSSVDSQPQSKSKNTWYIDEVAEDPAKSLTEISTDFDRSSPPLQPPPVNSLTTENRFHSLPFSLTKMPNTNGSIGHSPLSLSAQSVMEELNTAPVQESPPLAMPPGNSHGLEVGSLAEVKENPPFYGVIRWIGQPPGLNEVLAGLELEDECAGCTDGTFRGTRYFTCALKKALFVKLKSCRPDSRFASLQPVSNQIERCNSLAFGGYLSEVVEENTPPKMEKEGLEIMIGKKKGIQGHYNSCYLDSTLFCLFAFSSVLDTVLLRPKEKNDVEYYSETQELLRTEIVNPLRIYGYVCATKIMKLRKILEKVEAASGFTSEEKDPEEFLNILFHHILRVEPLLKIRSAGQKVQDCYFYQIFMEKNEKVGVPTIQQLLEWSFINSNLKFAEAPSCLIIQMPRFGKDFKLFKKIFPSLELNITDLLEDTPRQCRICGGLAMYECRECYDDPDISAGKIKQFCKTCNTQVHLHPKRLNHKYNPVSLPKDLPDWDWRHGCIPCQNMELFAVLCIETSHYVAFVKYGKDDSAWLFFDSMADRDGGQNGFNIPQVTPCPEVGEYLKMSLEDLHSLDSRRIQGCARRLLCDAYMCMYQSPTMSLYK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

CYLD-Ser341
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

CYLD-Ser358
Cancer	Intensity
BRCA
COAD	0.411
HGSC
ccRCC	0.723
GBM
HNSC
LUAD	0.346
LUSC
non_ccRCC
PDAC
UCEC	-1.48

CYLD-Ser359
Cancer	Intensity
BRCA	1.125
COAD	0.923
HGSC	-0.341
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC	-1.246
PDAC
UCEC	-0.461

CYLD-Ser362
Cancer	Intensity
BRCA
COAD
HGSC	-1.475
ccRCC	0.331
GBM
HNSC	1.296
LUAD	0.031
LUSC
non_ccRCC
PDAC
UCEC	-0.182

CYLD-Ser366
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-1.414
LUSC	0.122
non_ccRCC	0.921
PDAC
UCEC	0.371

CYLD-Ser384
Cancer	Intensity
BRCA	0.032
COAD
HGSC	-2.649
ccRCC	-0.097
GBM	-0.127
HNSC	0.762
LUAD	0.627
LUSC	0.72
non_ccRCC	0.479
PDAC	0.447
UCEC	-0.192

CYLD-Ser395
Cancer	Intensity
BRCA
COAD	0.333
HGSC	-1.124
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.791

CYLD-Ser396
Cancer	Intensity
BRCA	-0.611
COAD	0.666
HGSC	-1.356
ccRCC	0.15
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	1.15

CYLD-Ser406
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC
GBM
HNSC
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

CYLD-Ser415
Cancer	Intensity
BRCA	-1.406
COAD	-0.166
HGSC	2.624
ccRCC	-0.197
GBM	-0.067
HNSC	-0.794
LUAD	0.011
LUSC	0.201
non_ccRCC	0.333
PDAC	-0.536
UCEC	-0.003

CYLD-Ser419
Cancer	Intensity
BRCA	-0.105
COAD	-0.524
HGSC	-0.476
ccRCC	0.041
GBM	0.594
HNSC	-1.261
LUAD	0.144
LUSC	-0.15
non_ccRCC	2.656
PDAC	-0.353
UCEC	-0.566

CYLD-Ser544
Cancer	Intensity
BRCA	-0.225
COAD
HGSC	0.077
ccRCC	0.157
GBM	1.198
HNSC	-0.114
LUAD	-1.699
LUSC	-0.391
non_ccRCC	1.969
PDAC	-0.692
UCEC	-0.28

CYLD-Ser549
Cancer	Intensity
BRCA	-0.4
COAD	-0.164
HGSC	0.399
ccRCC	-0.005
GBM	-1.67
HNSC	1.342
LUAD	-0.55
LUSC	-1.005
non_ccRCC	1.098
PDAC	1.499
UCEC	-0.544

CYLD-Ser557
Cancer	Intensity
BRCA	0.69
COAD	0.328
HGSC	-2.601
ccRCC	-0.234
GBM	-0.781
HNSC	0.182
LUAD	0.366
LUSC	0.843
non_ccRCC	0.784
PDAC	0.661
UCEC	-0.238

CYLD-Ser565
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.151
GBM	-1.411
HNSC	0.32
LUAD	0.94
LUSC
non_ccRCC
PDAC
UCEC

CYLD-Ser836
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

CYLD-Tyr15
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

CYLD-Tyr563
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.165
GBM
HNSC	-0.908
LUAD	1.072
LUSC
non_ccRCC
PDAC
UCEC

CYLD-Tyr832
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb